Introduction March 20, 2026, marked a turning point in Indian healthcare. On that date, the patent on semaglutide — the active molecule behind blockbuster weight-loss and diabetes drugs Ozempic and… Continue Reading
Blogs
Weight Loss Drugs in India 2025–2026
Introduction India is in the middle of a quiet but profound health revolution. For decades, weight loss advice followed a familiar script eat less, move more, be patient. But in… Continue Reading
17 Cancer Drugs Just Became Duty-Free. Here’s What That Actually Changes
Finance Minister Nirmala Sitharaman’s customs duty wipeout on life-saving oncology medicines is making headlines — but the real story is in the details patients actually care about. India has roughly… Continue Reading
Ozempic India: ₹10K/Month or Wait for ₹3K Generics?
Ozempic’s India Launch: On December 12, 2025, Danish pharmaceutical giant Novo Nordisk launched its blockbuster diabetes drug Ozempic in India. The Drug Controller General of India (DCGI) granted approval in… Continue Reading
Yurpeak (Tirzepatide) by Cipla Now in India for Obesity or Type 2 Diabetes
Cipla Yurpeak (Tirzepatide) Cipla Limited has launched Yurpeak (tirzepatide), a once-weekly injectable therapy for obesity and type 2 diabetes under its marketing and distribution agreement with Eli Lilly and Company… Continue Reading